mRNA-1083
mRNA-1083 is Moderna's combination influenza and COVID-19 vaccine, designed as a single annual shot protecting against both respiratory viruses simultaneously. The vaccine delivers mRNA instructions encoding influenza hemagglutinin antigens alongside the SARS-CoV-2 spike protein, training the immune system to defend against both pathogens in one dose. A Phase 3 trial in adults aged 50 and older reported positive non-inferiority results versus licensed comparators in April 2026, supporting a planned BLA filing as Moderna's first non-COVID respiratory commercial candidate.
Programs
Seasonal Influenza
Seasonal influenza kills 290,000–650,000 people globally each year; current vaccines are manufactured with egg-based methods that vary in effectiveness and require separate administration from COVID-19 boosters. This Phase 3 trial tests mRNA-1083 as a single annual shot covering both influenza and COVID-19 for adults aged 50 and older; positive non-inferiority data versus licensed comparators were reported in April 2026, supporting a planned BLA filing.